CDK9 and cancer: In addition, studies have shown that the inhibitors of CDK7(THZ1) or CDK9(CYC065) can disrupt abnormal MYCN-driven transcription and inhibit MYCN gene transcription, becoming potential anti-cancer drugs [213,214].